25C-NBOH
4-chloro-2,5-dimethoxy-N-(2-hydroxybenzyl)phenethylamine
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
25C-NBOH is a synthetic psychedelic of the phenethylamine class. It is a structural variant of 25C-NBOMe, distinguished by a hydroxyl group replacing the methoxy on the benzyl ring. 25C-NBOH is a presumed 5-HT₂A receptor agonist with additional 5-HT₂C activity,[1] producing its effects by activating serotonin-driven signaling cascades in cortical circuits.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +5 moreLSD, psilocybin, mescaline, 25C-NBOMe, 25I-NBOMe, 25I-NBOH, other NBOMe/NBOH compounds, serotonergic psychedelics show less
The NBOH scaffold was developed at the University of Copenhagen by Hansen and Kristensen as part of systematic research into N-benzyl phenethylamine pharmacology.[3] 25C-NBOH appeared on the novel psychoactive substance market between 2014 and 2017, first identified in seized blotter papers in Brazil.[4] It remains unscheduled under United Nations conventions, though Brazil and individual US states have added specific NBOH compounds to controlled schedules.
Subjective effects include geometric visual patterns, color enhancement, conceptual thinking, emotional intensification, and boundary dissolution. The experience is described as more visually driven and somatically stimulating than tryptamine psychedelics, with a steep dose-response curve where small microgram-level variations produce large shifts in intensity. Nausea, anxious fixation, and a numbing or metallic taste from sublingual administration are common unsought effects.
25C-NBOH produces no physical dependence, and rapid tolerance makes compulsive redosing self-limiting. The primary risk is physiological: animal studies document QT prolongation and heart cell toxicity,[5] fatalities involving the closely related 25C-NBOMe are documented,[6][7] and microgram-active dosing creates elevated overdose potential. No clinical studies or controlled toxicology exist — the current understanding rests on class analogy, a single animal study, and forensic case reports.
History[edit]
Discovery
The N-benzyl phenethylamine psychedelic class originated with Ralf Heim's 2002 patent describing NBOMe derivatives of the 2C-X compounds.[2] The NBOH variant — substituting a hydroxyl for the methoxy group on the benzyl ring — was developed at the University of Copenhagen by Martin Hansen and Jesper L. Kristensen as part of systematic structure-activity research across 48 N-benzyl phenethylamines.[3][8] 25C-NBOH specifically has no recorded date of first synthesis; its existence is implicit in the systematic series but was never reported as a discrete event.
Market emergence
25C-NBOH appeared on the novel psychoactive substance market between approximately 2014 and 2017. Machado et al. published the first forensic identification, detecting 25C-NBOH in blotter papers seized by Brazilian law enforcement.[4] By the late 2010s, NBOH compounds had become the dominant hallucinogenic substances in seized blotter papers in Brazil, supplanting both LSD and NBOMe compounds — a shift driven by their unscheduled status in most jurisdictions at the time.
Regulatory history
No NBOH compounds are listed under any United Nations drug control conventions.[4] Brazil scheduled NBOH compounds including 25C-NBOH in December 2018.[9] In the United States, 25C-NBOH is not directly scheduled at the federal level, though the Federal Analogue Act may apply given its structural similarity to the Schedule I compound 25C-NBOMe. Detailed jurisdictional coverage appears in the Legal Status section.
The name 25C-NBOH follows the systematic naming convention of the N-benzyl phenethylamine class: "25" denotes the N-benzyl substitution of a 2C-X parent, "C" identifies the 4-chloro substituent from the parent compound 2C-C, and "NBOH" specifies the ortho-hydroxybenzyl group. This naming system allows rapid identification of both the phenethylamine core and the benzyl ring substitution pattern across a large compound family.
Chemistry[edit]
Structural class
25C-NBOH sits at the intersection of three structural families: the substituted phenethylamines, the 2C-X series, and the N-benzyl phenethylamines. The parent compound is 2C-C (2,5-dimethoxy-4-chlorophenethylamine), a member of the 2C-X series. Attaching a 2-hydroxybenzyl group to the nitrogen of 2C-C produces 25C-NBOH — a modification that dramatically increases binding strength at serotonin receptors.[3]
The NBOH designation marks the ortho-hydroxyl group on the benzyl ring, distinguishing this subfamily from the NBOMe series, which carries an ortho-methoxy group instead. This single functional group swap — phenol versus methyl ether — lowers lipophilicity, opens a direct metabolic pathway (glucuronidation), and alters how the molecule ionizes at body pH.[12]
Molecular identity
| Molecular formula | C₁₇H₂₀ClNO₃ |
| Molecular weight | 321.8 g/mol |
The molecule consists of a 2,5-dimethoxy-4-chlorophenethylamine core linked through a secondary amine to a 2-hydroxybenzyl group. The chlorine at position 4 defines the "C" in the 2C-X naming scheme. The two methoxy groups at positions 2 and 5 are essential for activity across the entire 2C-X and 25x series.[3] The hydroxyl on the benzyl ring acts as a hydrogen bond donor that contributes to receptor binding.
Stereochemistry
The secondary amine nitrogen does not form a stereocenter under normal conditions, as the N-benzyl group undergoes rapid inversion. 25C-NBOH is typically encountered as the racemic mixture free base or hydrochloride salt.
Physical properties
No peer-reviewed characterization of melting point, solubility, or stability has been published. The compound is distributed primarily on blotter paper impregnated with microgram quantities.[4] The free phenol group makes 25C-NBOH susceptible to oxidative breakdown.[12]
Standard gas chromatography methods can cause the molecule to decompose and be misidentified as the parent compound 2C-C; liquid chromatography-based methods are required for reliable identification.[4][13]
Pharmacology[edit]
Mechanism of action
25C-NBOH is presumed to produce its psychedelic effects primarily through strong activation of the serotonin 5-HT₂A receptor.[2][14] No binding affinity or potency measurements have been published for 25C-NBOH specifically — its mechanism is inferred from class-level structure-activity data established by Hansen et al. across 48 N-benzyl phenethylamines[3] and from direct studies of the closely related compound 25I-NBOH.[1]
When 25C-NBOH binds the 5-HT₂A receptor, it triggers a Gq protein signaling cascade that increases calcium levels inside neurons and alters gene expression.[2] Research by Wallach et al. demonstrated that this Gq pathway — rather than the alternative β-arrestin pathway — is what drives psychedelic effects; compounds that preferentially recruit β-arrestin instead block psychedelic activity.[15]
Additional activity at 5-HT₂C receptors is expected. Eshleman et al. found that 25I-NBOH activates both 5-HT₂A and 5-HT₂C with high potency, shows very weak activity at 5-HT₁A, and has negligible effects on monoamine transporters — a profile "consistent with hallucinogenic activity, with little psychostimulant activity".[1]
Whether 25C-NBOH shares the signaling bias patterns observed in other NBOH compounds remains unknown. Pottie et al. identified that 25H-NBOH shows a preference for β-arrestin recruitment over Gq activation compared to an LSD reference,[16] but equivalent data for the 4-chloro variant do not exist.
Pharmacokinetics
No human pharmacokinetic studies exist for 25C-NBOH. All parameters are inferred from the closely related 25I-NBOH and the broader NBOH class.
Sublingual administration is the primary documented route, based on forensic analysis of seized blotter papers.[4] Sublingual absorption bypasses the liver's first-pass metabolism, likely improving bioavailability compared to swallowing. No quantitative absorption, distribution, or clearance data have been published for any NBOH compound in humans.
Metabolism studies of 25I-NBOH in human liver tissue identified CYP2D6 as the primary metabolic enzyme — distinct from 25C-NBOMe, which relies on CYP3A4.[12] The compound also undergoes direct glucuronidation, an alternative clearance route that may reduce the impact of genetic variation in CYP2D6 activity.
Caspar et al. confirmed that 25C-NBOH is produced in the body as a metabolite when 25C-NBOMe is consumed,[11] and Kristofic et al. detected it in the blood and urine of a 25C-NBOMe fatality.[10] Duration data from user reports (total 5–7 hours, onset 15–45 minutes sublingual) have not been confirmed in controlled studies but are consistent with reported durations for the NBOH class.safety citation needed
Neuroscience[edit]
No direct neuroimaging, electrophysiological, or neurochemical data exist for 25C-NBOH. The following discussion draws on established mechanisms for serotonergic psychedelics acting through 5-HT₂A agonism and on preclinical data from the NBOH class.
Where it acts
As a presumed 5-HT₂A agonist, 25C-NBOH is expected to act on pyramidal neurons in the prefrontal cortex, where receptor activation increases excitability and disrupts the brain's normal filtering of sensory and cognitive information.[2] Preclinical studies using 25I-NBOH as a selective 5-HT₂A probe documented characteristic slow brainwave patterns and behavioral arrest in rodents — electrophysiological signatures of selective cortical activation.[17] The broader psychedelic neuroimaging literature consistently shows dissolution of the default mode network, increased global connectivity, and elevated neural entropy — effects mediated through 5-HT₂A receptors and blocked by the antagonist ketanserin.citation needed
Why it matters
The REBUS model proposes that 5-HT₂A agonists loosen the brain's confidence in its existing predictions, allowing raw sensory information greater influence on conscious experience — accounting for the pattern recognition enhancement, geometric visuals, and conceptual fluidity characteristic of the psychedelic state.citation needed Separately, 5-HT₂A agonists as a class promote rapid structural changes in neurons — new branches and synaptic connections — a property termed neuroplasticity.citation needed Whether 25C-NBOH shares this neuroplastic capacity has not been tested.
Key unknowns include whether 25C-NBOH promotes structural neuroplasticity at relevant doses, what its signaling bias profile looks like compared to related NBOH compounds, and whether CYP2D6 genetic variation[12] alters brain exposure and neural response. The relationship between the documented cardiac effects[5] and autonomic changes during the psychedelic state also remains unexplored.
Subjective Effects[edit]
The 25C-NBOH experience is shaped by its extreme dose sensitivity. Active at microgram quantities, the range between threshold and strong effects is narrow — small absolute changes in dose produce outsized shifts in intensity. Set, setting, and individual variation (potentially including genetic differences in drug metabolism) strongly modulate outcomes across the entire dose range. The sublingual route introduces a characteristic numbing or metallic taste that may prime anticipatory anxiety.
Within the serotonergic psychedelic landscape, 25C-NBOH occupies a position comparable to 25C-NBOMe in potency and duration, shorter and more abrupt than LSD. The N-benzyl phenethylamine class generally produces a more visually driven, somatically stimulating experience than the tryptamines, with a less introspective character at equivalent intensity — though no controlled comparisons have been conducted.
Effect Grid
A common dose produces a full psychedelic experience. Visual effects are pronounced — geometry, visual drifting, color enhancement, tracers, and symmetrical texture repetition are clearly present. Internal hallucinations may emerge. Cognitive effects include conceptual thinking, thought connectivity, pattern recognition enhancement, and emotional enhancement. Set and setting become major modulators of the experience.
Physical effects are notable: stimulation and wakefulness are reliable, with muscle tension, vasoconstriction, and possible temperature dysregulation. Nausea may occur during the come-up. Appetite is suppressed.
Full functional impairment — do not drive or operate machinery. Total duration approximately 5–7 hours with extended aftereffects possible over subsequent days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tracers · Brightness alteration · Music enhancement · Symmetrical texture repetition · Environmental patterning · Visual breathing · Perspective distortion · Auditory enhancement · Depth perception distortion · Visual diffraction · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Spatial disorientation · Visual haze / noise · Visual morphing · Holotropic state · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Visual melting · Visual acuity enhancement · Visual magnification · Peripheral misidentification · Synesthesia · After-images · Dreaming enhancement · Touch enhancement · Visual processing acceleration · Vestibular distortion · Touch suppression · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · Object activation · Visual scenery slicing · External hallucinations · Visual processing suppression · Auditory hallucinations · Perspective hallucinations · Gustatory hallucination · Visual flipping · Persisting hallucinations
Environmental patterning · Visual breathing · Perspective distortion · Auditory enhancement · Depth perception distortion · Visual diffraction · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Spatial disorientation · Visual haze / noise · Visual morphing · Holotropic state · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Visual melting · Visual acuity enhancement · Visual magnification · Peripheral misidentification · Synesthesia · After-images · Dreaming enhancement · Touch enhancement · Visual processing acceleration · Vestibular distortion · Touch suppression · Tinnitus · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · Object activation · Visual scenery slicing · External hallucinations · Visual processing suppression · Auditory hallucinations · Perspective hallucinations · Gustatory hallucination · Visual flipping · Persisting hallucinations
Wakefulness · Body high · Spontaneous body sensations · Muscle tension · Dry mouth · Appetite suppression · Restlessness · Heart rate perception changes · Insomnia · Physical fatigue · Bodily lightness · Nausea · Dehydration sensation · Headache · Dizziness · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily pressures · Body schema distortion · Breathing alteration · Excessive sweating · Motor control impairment · Tactile euphoria · Sexual arousal enhancement · Bodily heaviness · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Abnormal heartbeat · Increased urination · Bruxism · Vomiting · Seizure threshold reduction · Tactile hallucination
Muscle tension · Dry mouth · Appetite suppression · Restlessness · Heart rate perception changes · Insomnia · Physical fatigue · Bodily lightness · Nausea · Dehydration sensation · Headache · Dizziness · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily pressures · Body schema distortion · Breathing alteration · Excessive sweating · Tactile euphoria · Sexual arousal enhancement · Bodily heaviness · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Abnormal heartbeat · Increased urination · Bruxism · Vomiting · Seizure threshold reduction · Tactile hallucination
Immersion enhancement · Aesthetic enhancement · Openness enhancement · Thought connectivity · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Increased nature relatedness · Thought loops · Creativity enhancement · Humor enhancement · Confusion · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Analysis enhancement · Cognitive dysphoria · Memory replays · Amnesia
Thought connectivity · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Memory suppression · Cognitive fatigue · Cognitive impairment · Focus suppression · Increased nature relatedness · Thought loops · Creativity enhancement · Humor enhancement · Confusion · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Analysis enhancement · Cognitive dysphoria · Memory replays
Anxiety · Empathy enhancement · Catharsis · Dysphoria
Depersonalization · Trust enhancement · Communication enhancement · Flow state · Sociability enhancement · Boundary dissolution · Ego dissolution · Cognitive disconnection · Identity alteration
Sociability enhancement · Boundary dissolution · Ego dissolution · Cognitive disconnection · Identity alteration
Transpersonal visions · Entity contact · Death-rebirth sequence
Mindfulness enhancement · Recursive awareness
Timeline
Sublingual absorption begins with characteristic numbing or metallic taste at the administration site. First alerts include mild body awareness, subtle perceptual brightening, and faint stimulation.
Progressive intensification of visual and somatic effects. Body load (nausea, muscle tension) typically peaks during this phase. Geometry and color enhancement emerge.
Full expression of visual geometry, color enhancement, conceptual thinking, and emotional intensification. Maximum perceptual and cognitive alteration. Set and setting exert strongest influence on experiential direction.
Gradual reduction in visual intensity and cognitive alteration. Stimulation and wakefulness may persist after visual effects resolve. Appetite begins to return.
Residual mood and perceptual shifts over hours to days. Enhanced pattern recognition, altered emotional baseline, and mild visual anomalies may persist. The extended aftereffect period (up to several days per user reports) may reflect 5-HT2A receptor downregulation.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for 25C-NBOH in any species. The safety profile is reconstructed from a single animal study directly testing the compound, class-level data from the NBOMe series, and forensic case reports.
Acute toxicity
No published fatality has been specifically attributed to 25C-NBOH as the primary ingested substance.safety citation needed The characterization of potential lethality at high doses is extrapolated from 25C-NBOMe fatalities.
Documented 25C-NBOMe deaths include a young male who died 12 hours after ingestion with signs of serotonin syndrome,[6] and a teenager who drowned following agitation and confusion after ingesting 25C-NBOMe and 25H-NBOMe.[7] Severe intoxication with analytically confirmed 25C-NBOMe has been separately documented.[18] Kristofic et al. detected 25C-NBOH alongside 25C-NBOMe in a fatal case, confirming human exposure to 25C-NBOH as a metabolite.[10]
The broader NBOMe class toxicity profile includes seizures, extreme agitation, muscle breakdown, blood clotting disorders, dangerously low blood sugar, metabolic acidosis, and multi-organ failure.[19][20][14] These outcomes are plausible for 25C-NBOH given the shared receptor target, but none have been confirmed with the compound directly.
Heart toxicity
The only published study directly testing 25C-NBOH found significant cardiac effects in animal models.[5] The compound dramatically decreased survival of heart muscle cells in laboratory tests and caused QT prolongation (a marker of dangerous heart rhythm changes) and slowed heart rate in live rats.
These findings establish a direct cardiac safety concern, though all data are from animal models. The human cardiac safety profile is unknown.
Stimulant-like crisis
At excessive doses, the NBOH and NBOMe class produces a stimulant-like crisis: rapid heart rate, elevated blood pressure, dangerously high body temperature, and dilated pupils.[14] In a clinical series involving 25B-NBOMe, 7 of 10 patients required high-dose sedation for severe agitation.[19]
Psychological Risks
No systematic data on psychological adverse effects exist for 25C-NBOH specifically. Class-level evidence from NBOMe intoxications documents severe anxiety, paranoia, agitation, confusion, and uncontrollable violent behavior at high doses.[14][19]
The risk of persistent visual disturbances (HPPD), prolonged psychosis, or other lasting psychiatric effects has not been studied for 25C-NBOH. These risks are recognized for serotonergic psychedelics as a class and are presumed to apply, particularly given the high potency and strong receptor activation characteristic of N-benzyl phenethylamines.safety citation needed
The microgram-range dosing and steep dose-response curve create an elevated risk of unintentional overdose, compounding both physical and psychological harms.
Tolerance and Dependence
Tolerance builds almost immediately after ingestion, with a reported half-life of approximately one week and full reset at approximately two weeks.safety citation needed The mechanism is presumed to involve rapid 5-HT₂A downregulation.[2][15]
Cross-tolerance with other serotonergic psychedelics — including LSD, psilocybin, and other NBOH/NBOMe compounds — is expected but has not been experimentally confirmed for 25C-NBOH.
25C-NBOH is not considered habit-forming. Serotonergic psychedelics generally carry low abuse liability because they do not activate the brain's reward circuits. The negligible activity at dopamine, serotonin, and norepinephrine transporters documented for 25I-NBOH[1] is consistent with minimal reinforcement potential.
Drug Interactions
The interaction profile is shaped by two features: potent 5-HT₂A activation and CYP2D6-dependent metabolism. No substance-specific interaction studies have been published.
Serotonergic combinations
The most dangerous interaction involves drugs that increase serotonin levels. Tramadol combines serotonin reuptake inhibitor with opioid effects; adding a potent 5-HT₂A agonist substantially elevates the risk of serotonin syndrome[21] — a potentially fatal condition involving muscle rigidity, dangerously high body temperature, rapid heart rate, and mental status changes.[22]
Monoamine oxidase inhibitors, SSRIs, SNRIs, and triptans carry similar additive serotonergic risk.[22]
Metabolic interactions
Drugs that inhibit CYP2D6 (including fluoxetine, paroxetine, bupropion, and quinidine) could slow the breakdown of 25C-NBOH and raise blood levels.[12] Several of these (fluoxetine, paroxetine) also increase serotonin, creating a dual risk through both slowed elimination and increased serotonergic activity.
Stimulants
Combining with stimulants increases the risk of dangerously high body temperature — a documented contributor to fatal outcomes in the NBOMe class.[14]
Cannabis
The interaction between 25C-NBOH and cannabis is uncharacterized. Cannabis is commonly co-used with psychedelics and may intensify subjective effects, but no specific safety data exist for this combination.
Contraindications
No substance-specific contraindication data have been published. The following are inferred from the compound's pharmacological profile and class-level evidence:
- Heart conditions: The documented QT prolongation[5] and heart cell toxicity make pre-existing heart rhythm disorders, congenital long QT syndrome, and structural heart disease absolute contraindications. Other QT-prolonging medications amplify this risk.
- Seizure disorders: Seizures are documented in NBOMe/NBOH class intoxications.[19][20] Pre-existing epilepsy or lowered seizure threshold is an absolute contraindication.
- Psychiatric conditions: Personal or family history of psychotic disorders represents a relative contraindication, consistent with the class-level risk of serotonergic psychedelics precipitating psychotic episodes.
- MAO inhibitor therapy: Concurrent use creates life-threatening serotonin syndrome risk.
- Liver impairment: CYP2D6-dependent metabolism[12] suggests impaired clearance, though the direct glucuronidation pathway provides partial redundancy.
- Pregnancy: No reproductive toxicity data exist. Standard precautionary contraindication applies.
Harm Reduction[edit]
Forms & Identification
The blotter format that dominates 25C-NBOH distribution is visually indistinguishable from LSD, NBOMe compounds, and other NBOH variants. A bitter, numbing, or metallic taste on the tongue is characteristic of the NBOH and NBOMe classes and serves as a key differentiator from LSD, which is tasteless. This taste test is not diagnostic — it cannot distinguish between different N-benzyl compounds — but the presence of any strong taste on blotter confirms the substance is not LSD.
Reagent testing narrows identification but may not differentiate between closely related NBOH and NBOMe compounds. Quantitative laboratory analysis (such as drug-checking services) is the only reliable method for confirming identity and dose.
Guidelines
- Test every sample with reagent kits before use — the blotter format carries high substitution risk
- Start with the lowest reported active dose and wait the full onset period (up to 45 minutes sublingual) before considering any increase
- Avoid redosing — tolerance builds immediately and the temptation to redose during a slow onset accounts for a significant proportion of adverse experiences
- Ensure access to water and a comfortable place to sit or lie down
- Avoid driving, swimming, heights, and any environment where impaired coordination poses a physical danger
- Keep the setting calm and the group small — overstimulation amplifies anxiety at high effect levels
- Have a sober companion present who knows what substance was taken and at what dose
Set & Setting
The steep dose-response curve and microgram-level potency of 25C-NBOH make psychological and environmental preparation especially important. Small differences in dose translate to large differences in intensity, and overwhelming experiences can escalate rapidly.
A familiar, physically safe, low-stimulation environment reduces the likelihood of anxiety escalation. A trusted, sober companion who can provide reassurance and practical support is strongly recommended, particularly for anyone without prior experience with high-potency phenethylamine psychedelics.
Aftercare & integration. The 5–7 hour duration of 25C-NBOH typically leaves residual stimulation and altered perception for several hours after the primary effects subside. Sleep may be difficult for 2–4 hours after the experience ends.
Eat light, easily digestible food when appetite returns. Hydrate steadily but without forcing fluids. Avoid making significant decisions or engaging in demanding tasks for 24 hours.
If the experience was intense or distressing, writing or speaking about it within the first few days can help process the content. Recurring intrusive imagery, persistent anxiety, or visual disturbances lasting more than a few days warrant consultation with a mental health professional experienced with psychedelic-related concerns.
Recovery & Support
25C-NBOH does not produce physical dependence, and compulsive use patterns are rare due to rapid tolerance. However, repeated use of high-potency psychedelics can reflect broader patterns of psychological distress or avoidance.
If psychedelic use has become a way of managing emotional difficulty rather than a deliberate, spaced practice, speaking with a counselor or therapist can help clarify the pattern. Peer support communities such as the Fireside Project (psychedelic peer support line) and integration circles offer non-clinical spaces to process difficult experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Uncomfortable anxiety, nausea, and confusion are distressing but typically self-limiting. Seek immediate help if any of the following occur: seizure activity, loss of consciousness, chest pain or irregular heartbeat, body temperature that feels dangerously hot to the touch, violent agitation or total disconnection from reality with risk of self-harm, or breathing difficulties.
Immediate steps
- Call emergency services immediately if any of the above signs are present
- Move the person to a safe, quiet space away from hazards
- Do not restrain unless there is immediate danger of self-harm — restraint can worsen agitation
- Keep them cool — remove excess clothing, apply cool water if overheating
- If unconscious and breathing, place in the recovery position (on their side, airway clear)
- Do not induce vomiting — sublingual absorption means the substance is already in the bloodstream
- Stay with them until help arrives
What to tell the dispatcher
State the substance name (25C-NBOH or "an NBOH psychedelic compound"), the approximate dose if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for medical help during a drug emergency.
Legal Status[edit]
25C-NBOH occupies a fragmented regulatory position distinct from its NBOMe structural counterpart. No NBOH compounds are listed under any United Nations drug control conventions,[4] and scheduling has proceeded through national-level action rather than harmonized international treaties. The single functional group difference between 25C-NBOH and the scheduled compound 25C-NBOMe — a hydroxyl versus a methoxy group on the benzyl ring — may or may not fall within generic scheduling definitions depending on jurisdiction.
Legal status information was compiled from published academic sources and government documents. Laws change frequently, and the information below may not reflect current regulations. Verify legal status through official government sources before making decisions based on this information.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Nations | Not controlled | No NBOH compounds listed under any UN drug control convention[4] |
| United States | Not directly scheduled (federal) | 25C-NBOMe is Schedule I (2013). 25C-NBOH may constitute a Controlled Substance Analogue under the Federal Analogue Act when intended for human consumption. Louisiana: 25I-NBOH specifically listed as Schedule I (June 2013)citation needed |
| United Kingdom | Likely controlled | NBOMe compounds controlled under Class A via 2014 Amendment Order to Misuse of Drugs Act 1971.[23] Whether NBOH compounds fall within the generic definition is unresolved. Psychoactive Substances Act 2016 provides additional blanket coverage |
| Brazil | Controlled | NBOH compounds including 25C-NBOH scheduled December 2018[9] |
| Australia | Variable by state | State-level analogue provisions may apply. No specific national scheduling confirmed for NBOH compounds |
| European Union | Variable by member state | No harmonized EU-level control. May be covered under national generic or blanket NPS legislation in individual member states |
Analogue considerations
The structural relationship between 25C-NBOH and the Schedule I compound 25C-NBOMe is both pharmacologically and legally significant. The two compounds differ by a single oxygen atom, share the same phenethylamine core, and produce qualitatively similar effects through the same receptor target. In jurisdictions with structural analog legislation (such as the US Federal Analogue Act), this similarity may render 25C-NBOH a de facto controlled substance when sold or possessed with intent for human consumption, even without specific scheduling.
25C-NBOH is also a principal metabolite of 25C-NBOMe,[10][11] creating forensic ambiguity: detection of 25C-NBOH in biological specimens does not unambiguously establish which compound was consumed.
references
- [1] ^abcdEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4]
- [5] ^abcdYoon KS, Cha HJ, Choi SO, Lee JM (2022) 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system — Toxicology Letters doi:10.1016/j.toxlet.2021.11.016
- [6] ^abcAndreasen MF, Telving R, Rosendal I, Eg MB, Hasselstrøm JB, Andersen LV (2015) A fatal poisoning involving 25C-NBOMe. — Forensic Science International doi:10.1016/j.forsciint.2015.03.012